International Society of Oncology Pharmacy Practitioners (ISOPP) believes that oncology pharmacists have a crucial role to play in the implementation and optimal use of biosimilar medicines in clinical practice. To support oncology pharmacists in fulfilling this role, in 2018 the Secretariat of ISOPP formed a Biosimilars Task Force to review the available evidence, and to discuss the challenges and opportunities presented by the introduction of biosimilars into the oncology and supportive care setting and how these could be addressed.
ISOPP’s Publication on Biosimilars is published as a supplement in the Journal of Oncology Pharmacy Practice (JOPP), and consists of the following four papers:
- International Society of Oncology Pharmacy Practitioners Global Position on the Use of Biosimilars in Cancer Treatment and Supportive Care
- Proceedings of the Biosimilars Workshop at International Symposium on Oncology Pharmacy Practice 2019 (ISOPP 2019)
- Assessing Biosimilar Education Needs Among Oncology Pharmacy Practitioners Worldwide: An ISOPP Membership Survey
- A Survey of Global Biosimilar Implementation Practice conducted by the International Society for Oncology Pharmacy Practitioners
This supplement serves as a collection of the findings and educational resources generated by the Biosimilar Task Force to date. We hope that these documents will facilitate the safe and effective use of biosimilars in clinical practice, and provide guidance and expertise to pharmacists around the world on the use of biosimilar products.
Thank you to the Biosimilars Task Force members for all their hard work and dedication in bringing the publication to fruition.